Figure 1.

Acute MCMV (Δm157) infection abrogates tolerance induction by donor ECDI-SPs. (A) Schematic treatment plan of tolerance induction in B6 transplant recipients. Donor (Balb/c) ECDI-SPs (1×10⁸) were infused IV on day −7 and +1. Approximately 200 Balb/c islets were implanted in the kidney capsule of diabetic B6 recipients on day 0. (B) Percent graft survival of islet allografts in uninfected or Δm157-infected recipients, with the infection given on day 0. Data shown in panel B were from at least 5 independent experiments with a total of 10 to 18 mice in each group. (C) Percent graft survival of islet allografts in uninfected or Δm157-infected recipients, with the infection given on day 7. Data shown in panel C were from 2 independent experiments with a total of 5 to 6 mice in each group. (D) Detection of MCMV DNA in the spleen and islet isograft following Δm157 infection. MCMV MEIP gene was quantified by quantitative polymerase chain reaction. Data were normalized to values from tissues of uninfected hosts and presented as mean ± SD (N = 4). (E) Sygeneic transplantation. Percent graft survival of islet isografts in uninfected or Δm157-infected recipients, with the infection given on day 0. *P < .05 (log-rank test). Data presented in panels D and E were compiled from 2 independent experiments with a total of 4 mice in each group.